AIMS: Several lines of evidence indicate that axon guidance genes are involved not only in neural development but also in cancer development. ROBO1 and ROBO2, crucial regulators of axon guidance, are considered potential tumour suppressor genes. The aim of this study was to explore whether ROBO1 and ROBO2 genes are somatically mutated and expressionally altered in gastric (GC) and colorectal cancers (CRC). METHODS: In a public database, we observed that both ROBO1 and ROBO2 had mononucleotide repeats in their coding exons that could be mutation targets in cancers with microsatellite instability (MSI). We analysed mutations of these repeats in 77 GC and 88 CRC either with high MSI (MSI-H) or low MSI/microsatellite stability (MSI-L/MSS) by single-strand conformation polymorphism (SSCP) and DNA sequencing. We analysed ROBO1 and ROBO2 expressions in GC and CRC by immunohistochemistry as well. RESULTS: Overall, we found five ROBO1 and five ROBO2 frameshift mutations in the repeats. They were detected exclusively in the cancers with MSI-H (10/70, 14.2%), but not in MSI-L/MSS (0/95, 0%) (p=0.018). In the immunohistochemistry, loss of ROBO2 expression was identified in 22 (29%) and 17 (19%) of GC and CRC, respectively, while increased expression of ROBO2 was found in 15 (20%) and 22 (25%) of GC and CRC, respectively. There were co-occurrences of mutation and loss of expression in both ROBO1 (4/5, 80% mutated cases, p<0.001) and ROBO2 (5/5, 100% mutated cases, p<0.05) genes. CONCLUSION: This is the first report of ROBO1 and ROBO2 frameshift mutations in GC and CRC. Frameshift mutations of ROBO1 and ROBO2 genes and alteration of ROBO2 expression in GC and CRC suggest that both genes might play roles in the pathogenesis of GC and CRC.
AIMS: Several lines of evidence indicate that axon guidance genes are involved not only in neural development but also in cancer development. ROBO1 and ROBO2, crucial regulators of axon guidance, are considered potential tumour suppressor genes. The aim of this study was to explore whether ROBO1 and ROBO2 genes are somatically mutated and expressionally altered in gastric (GC) and colorectal cancers (CRC). METHODS: In a public database, we observed that both ROBO1 and ROBO2 had mononucleotide repeats in their coding exons that could be mutation targets in cancers with microsatellite instability (MSI). We analysed mutations of these repeats in 77 GC and 88 CRC either with high MSI (MSI-H) or low MSI/microsatellite stability (MSI-L/MSS) by single-strand conformation polymorphism (SSCP) and DNA sequencing. We analysed ROBO1 and ROBO2 expressions in GC and CRC by immunohistochemistry as well. RESULTS: Overall, we found five ROBO1 and five ROBO2 frameshift mutations in the repeats. They were detected exclusively in the cancers with MSI-H (10/70, 14.2%), but not in MSI-L/MSS (0/95, 0%) (p=0.018). In the immunohistochemistry, loss of ROBO2 expression was identified in 22 (29%) and 17 (19%) of GC and CRC, respectively, while increased expression of ROBO2 was found in 15 (20%) and 22 (25%) of GC and CRC, respectively. There were co-occurrences of mutation and loss of expression in both ROBO1 (4/5, 80% mutated cases, p<0.001) and ROBO2 (5/5, 100% mutated cases, p<0.05) genes. CONCLUSION: This is the first report of ROBO1 and ROBO2 frameshift mutations in GC and CRC. Frameshift mutations of ROBO1 and ROBO2 genes and alteration of ROBO2 expression in GC and CRC suggest that both genes might play roles in the pathogenesis of GC and CRC.
Authors: H Kadara; M Choi; J Zhang; E R Parra; J Rodriguez-Canales; S G Gaffney; Z Zhao; C Behrens; J Fujimoto; C Chow; Y Yoo; N Kalhor; C Moran; D Rimm; S Swisher; D L Gibbons; J Heymach; E Kaftan; J P Townsend; T J Lynch; J Schlessinger; J Lee; R P Lifton; I I Wistuba; R S Herbst Journal: Ann Oncol Date: 2017-01-01 Impact factor: 32.976
Authors: Rolando A R Villacis; Francine B Abreu; Priscila M Miranda; Maria A C Domingues; Dirce M Carraro; Erika M M Santos; Victor P Andrade; Benedito M Rossi; Maria I Achatz; Silvia R Rogatto Journal: Tumour Biol Date: 2015-10-01
Authors: Alba Mota; Juan Carlos Triviño; Alejandro Rojo-Sebastian; Ángel Martínez-Ramírez; Luis Chiva; Antonio González-Martín; Juan F Garcia; Pablo Garcia-Sanz; Gema Moreno-Bueno Journal: BMC Cancer Date: 2015-11-30 Impact factor: 4.430
Authors: Stephano S Mello; Carolyn Sinow; Nitin Raj; Pawel K Mazur; Kathryn Bieging-Rolett; Daniela Kenzelmann Broz; Jamie F Conklin Imam; Hannes Vogel; Laura D Wood; Julien Sage; Tetsuro Hirose; Shinichi Nakagawa; John Rinn; Laura D Attardi Journal: Genes Dev Date: 2017-07-11 Impact factor: 11.361